The industry built on a number you were never given

Somewhere right now it's three in the morning and a man is reading an advert.

He isn't stupid or gullible. He has been carrying a specific worry since he was about thirteen, has never said it out loud, has never seen a reliable figure, and has just been served a page that addresses that worry with total confidence and a money-back guarantee.

That's not a marketing problem, it's a market. Worth billions, and sitting in the space left empty by the fact that nobody ever told him the number.

So let's do what the adverts never do and go through the peer-reviewed literature on each of these products in turn, without flinching.

Surgery: the honest arithmetic

In 2008 Yoram Vardi's group published a systematic review in *European Urology* covering four decades of penile enhancement procedures on men with normal anatomy. It's the closest thing this field has to a reckoning, and it isn't ambiguous.

The headline figure: enhancement surgery generally produces 1 to 2 cm of extra length, and around 2.5 cm of girth.

Then comes the rest of the paragraph, the part that never reaches the brochure. Across the studies the review surveyed, it reported penile deformity. Paradoxical shortening, meaning an operation for length that leaves a man shorter. Unpleasant scarring. Granuloma formation. Migration of injected material. Sexual dysfunction.

And satisfaction: short-term and long-term patient satisfaction after these procedures was, in the review's own framing, disappointing in most of the studies examined.

Read that back as a trade. One to two centimetres on offer. Against it, a documented risk of deformity, scarring, migration and dysfunction. And the men who took the trade before you were, on average, not happy afterwards.

Everything else, briefly

The non-surgical market is bigger, cheaper and almost entirely unevidenced. Working through it:

1. —Pills and supplements. No oral compound has credible evidence of increasing penis size. None of them. The category survives because most jurisdictions regulate supplements as food rather than medicine, so a product can be sold without ever demonstrating that it does anything. Some contain undisclosed pharmaceutical ingredients, which makes them a safety problem rather than just a waste of money.
2. —Vacuum pumps. These do something real, drawing blood into the tissue to produce a temporary swelling, and they have a legitimate clinical role in erectile dysfunction and in rehabilitation after certain treatments. Permanent enlargement isn't among their effects. Used aggressively they cause bruising, burst blood vessels and tissue damage.
3. —Extenders and traction devices. The most defensible category, in that there's a plausible mechanism and some clinical use in conditions such as Peyronie's disease. For healthy men the evidence of meaningful gain is thin, and the protocols mean wearing a traction device for hours a day, every day, for months on end. That's the honest version of the offer.
4. —Jelqing and manual exercises. No evidence base at all. There are case reports of injury from repetitive forceful manipulation, including vascular damage and scarring. This is the one that passes between teenagers for free, which makes it simultaneously the most practised and the least examined.
5. —Injectable fillers. Temporary girth increase. Migration, nodule formation and asymmetry all appear in the literature as complications, and the material doesn't stay where it was put.

There's a pattern in that list worth naming. The interventions with the best safety profiles do the least, and the ones that do the most have the worst outcomes. I don't think that's coincidence or a gap in the research. It's what a market looks like when it's selling a solution to a problem that isn't physically located where the product goes.

Sixty-seven men in Florence

I keep coming back to the Mondaini study, and I'll raise it again here, because in this context it stops being poignant and turns into an indictment.

Sixty-seven men presented at a urology clinic asking to be surgically lengthened. All of them were measured. None was short. None had any anatomical abnormality.

Now picture those same sixty-seven men walking into a less careful clinic, somewhere with a private cosmetic-surgery market and an advertising budget. Nobody measures them against a reference range and tells them they're normal. They get quoted a price.

The industry's core competency isn't lengthening. It's not measuring. Every step of a well-run enhancement funnel exists to move a man from anxiety to purchase without a reference distribution ever entering the room, since the reference distribution is the one thing that would end the transaction.

Which is why the international position papers on men who present with size concerns all begin in the same place: measure the patient, show him where he sits, treat the distress rather than the anatomy. Reassurance and psychological support instead of a scalpel. That guidance exists because the field watched what happened when it was ignored.

The one intervention with an excellent evidence base

There is a treatment for this that works, costs nothing, and has been sitting in the literature for twenty years while the market sold pills over the top of it.

Being shown the actual distribution.

That's the whole intervention. Measure, compare against a clinician-derived nomogram, explain what the spread means, and for a large majority of men the distress resolves or drops substantially, because the belief driving it was wrong and had never been tested against data.

It doesn't work for everyone. A minority have genuine body dysmorphic disorder focused on this feature, and information alone won't touch that. The condition is well characterised and responds to psychological treatment rather than to reassurance or surgery, and I don't want to flatten that distinction.

For the ordinary case, though, the man at three in the morning with the advert open, the effective intervention is a number nobody has given him and a spread he has never seen. It's free. It's on this website. It's on the NHS website. It's in every study linked at the foot of this page.

The industry's entire margin lives in the gap between that and the fact that nobody ever tells him.

If you take one thing from this piece, take this. Before spending money, spend ten minutes with a nomogram. If the distress is still there once you have seen where you actually sit, and for some men it will be, then it's real and worth taking to a doctor or a therapist. They will take it seriously, and they have treatments aimed at what is actually happening.

What it isn't worth is a credit card at three in the morning.